Patient reviews are urged as inhaler switch looms

Any patients still being prescribed a Beclazone inhaler will need to be reviewed and transferred to another therapy ahead of the product's discontinuation next month.

Although other CFC-containing beclometasone dipropionate inhalers are no longer marketed in the UK following the Montreal Protocol, Beclazone has until now remained available.

Teva UK has now announced that all strengths of Beclazone will be discontinued on 31 March.

Patients should be reviewed and transferred to other treatments, the company said.

A spokeswoman for Teva said that 80 per cent of patients treated with beclometasone CFC-containing inhalers had already been transferred to CFC-free alternatives.

'The discontinuation should not compromise patients' asthma management as a range of alternative products are available,' she said.

Differences in dose availability meant that CFC-free beclometasone dipropionate inhalers are not interchangeable and the MHRA has said that these products should be prescribed by brand.

Dr Kevin Gruffyd-Jones, clinical policy lead for the General Practice Airways Group, said it was important healthcare professionals knew about the discontinuation so they could review patients still being treated with Beclazone and move them to other treatments.

Teva is not planning to contact healthcare professionals directly about the discontinuation of Beclazone. However, information and guidance on transferring patients to alternative products is available from the Teva medical information department on 020 7540 7117.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in